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ABSTRACT 
High Grade Serous Ovarian Cancer (HGSOC) is one of the deadliest 
gynecological diseases in the United States ranking fifth in cancer deaths among 
women.  Approximately 22 thousand new cases are expected to occur in the 
year 2020, and unfortunately, it is estimated that 14 thousand women will 
succumb to the disease; the incidence to death ratio, 64%, remains high despite 
current research. Current treatment includes debulking surgery followed by 
combinatorial chemotherapeutics with platinum-based and taxol-based 
compounds. But despite aggressive surgery and standard-of-care 
chemotherapeutics, 80% of patients will experience a recurrence and only 15-
30% of those with recurring disease will respond to further treatment.  
Tumors consist of a heterogeneous population of cell types. A small minority of 
tumor cells, called cancer stem cells (CSCs), can self-renew and differentiate 
and are thought to be responsible for recurrent, chemoresistant disease. A 
cancer cell’s ability to migrate and invade other tissues is a hallmark of 
metastatic disease. 
To invade, cells must undergo a process called an epithelial-mesenchymal 
transition (EMT) in which epithelial genes such as CDH1, which codes for E-
Cadherin (E-CAD), a cell-cell adhesion molecule, are repressed by the 
transcription factor SNAI1 (Snail) and genes associated with a mesenchymal 
phenotype, such as CDH2, which codes for N-Cadherin (N-CAD) are 
upregulated. This switch from epithelial to mesenchymal gene expression leads 
iv 
to migratory and invasive properties in cells. Cancer cells that express both 
epithelial and mesenchymal markers are considered hybrid (E/M) cells and are 
associated with increased tumor-forming ability and exhibit more cancer stem-
cell (CSC) like characteristics.  
Of those diagnosed with HGSOC, 50% exhibit a defect in their ability to repair 
DNA via homologous recombination (HR). In 20% of cases HR deficiency is 
caused by a mutation in the breast cancer susceptibility (BRCA) 1 or 2 gene 
which code for proteins that participate in the HR pathway. HR deficient cancer 
cells rely heavily on the poly (ADP-Ribose) polymerase (PARP) family of proteins 
to repair DNA damage. For this reason, PARP inhibitors have recently been 
employed as an adjuvant to chemotherapy to induce synthetic lethality, but some 
cancers develop a resistance which renders the therapy ineffective. In addition, 
some studies suggest that the use of PARP inhibitors, such as olaparib, enrich 
for cell surface markers CD133+ & CD117+. These markers are indicative of the 
cancer stem cell phenotype in HGSOC.  Although use of PARP inhibitors has 
increased progression-free survival, more information regarding the PARP 
protein and its functions is needed.  
In this study, we characterized six patient derived samples according to their 
functional capabilities related to invasiveness, chemoresistance and CSC 
properties and evaluated these capabilities in parallel with their EMT status. We 
found that certain EMT sub-types exhibit different capabilities and the most 
hybrid sub-type, E/M hybrid, are the most aggressive in tumor formation. This 
v 
data suggests that determining  EMT status could be valuable in predicting 
patient outcomes and developing personalized therapies.  
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CHAPTER ONE 
 
INTRODUCTION 
 
1.6 High Grade Serous Ovarian Carcinoma (HGSOC) 
In the United States alone, HGSOC is the fifth leading cause of cancer 
related deaths among women. It is estimated that in 2020 there will be 21,750 
new ovarian cancer cases diagnosed and 13,940 women will die from the 
disease (1). Characterized by the formation of malignant cells in the epithelium 
of the ovary, fallopian tube or peritoneum, more than half of those diagnosed 
with epithelial ovarian cancer (EOC) will succumb to the disease within five 
years (Figure 1). 
  
Figure 1: Peritoneal spread of ovarian Cancer. Ovarian cancer can arise from 
epithelial cells from the ovary, fallopian tube or peritoneum. 
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Due to the lack of specific signs and symptoms in the early stages of 
HGSOC, the disease often goes undiagnosed until it is in advanced stages and 
has formed metastases in the peritoneal cavity or at distant sites such as lung or 
liver (2).  
Currently, first-line treatment consists of debulking surgery followed by 
combinatorial chemotherapy with a platinum-based compound, such as cisplatin 
or carboplatin, and a taxane-based compound, such as paclitaxel or docetaxel 
(3). Unfortunately, despite receiving these treatments, approximately 80% will 
experience a recurrence and only 15-30% with recurring disease will respond to 
further treatment (4). Despite many years of ovarian cancer research, debulking 
surgery followed by chemotherapy remains the best treatment for the disease, 
but ovarian cancer mortality rates remain high compared to other gynecological 
cancers such as uterine, breast and cervical cancer (5) . Due to lack of early 
symptoms and the high mortality rate of women with ovarian cancer, more 
research is needed to understand the nature of the disease and, hopefully, save 
the lives of those afflicted.  
 
1.2 Cancer Stem Cells (CSC’s) 
Stem cells are cells that have the capacity to self-renew and differentiate.  
Embryonic stem (ES) cells are derived from the inner cell mass of a blastocyst 
and are pluripotent, meaning, they can differentiate into all tissue types within 
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any given organism (6). Once an organism is fully developed, a small population 
of adult stem cells remains in the tissues and is restricted to the lineage in which 
they reside (7). Adult stem cells have long-term self-renewal capabilities which 
enables them to be available throughout the life-span of the organism, remaining 
dormant until they are needed to replenish cells that have been damaged (7). 
Similar to adult tissues, tumors also consist of a heterogeneous population of 
cells that includes highly differentiated specialized cells as well as a small 
population of cells that can self-renew and differentiate into the highly specialized 
types.  Self-renewal and differentiation are the defining characteristics of stem 
cells, so stem-like cells within the tumor, cancer stem cells (CSCs), are believed 
to be responsible for the growth and maintenance of the tumor (Figure 2) (8). 
CSCs also possess many mechanisms that enable them to elude the harmful 
effects of chemotherapeutic drugs. Such mechanisms include enhanced DNA 
damage repair and over-expression of ABC efflux transporters (9). Surviving 
initial chemotherapy treatment, the CSCs dissociate from the primary tumor site 
and form secondary tumors at distant sites resulting in metastatic disease that no 
longer responds to chemotherapeutic drugs (10). Like adult stem cells, CSC’s 
represent a small population within the tumor and are quiescent which makes 
them difficult to target. In research, the identification of CSC’s relies heavily on 
the presence of  a combination of markers such as  CD133, CD44, CD24, 
EpCAM, ALDH1 and CD117, which are commonly used to determine CSC 
populations within ovarian tumors (11).  
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Figure 2: Cancer stem cell theory of tumor relapse. Conventional therapy destroys 
specialized cells within the tumor, but CSC’s evade these therapies and survive to 
regenerate the tumor. (Photo Credit: Harvard Stem Cell Institute. Stem cells and 
cancer, winter 2008 (vol 3, no 1)) 
 
 
1.3 Epithelial – Mesenchymal Transition Induced Invasiveness 
An epithelial – mesenchymal transition (EMT) is a biological process that 
results in epithelial cells losing their apical-basal properties and acquiring a 
mesenchymal phenotype. The mesenchymal phenotype is associated with 
elongated, spindle-like morphology as well as acquisition of migratory abilities 
(12). This migratory behavior is necessary in some biological processes such as 
development and tissue regeneration in which cells that were successful in 
reaching their intended location, undergo the opposite process, mesenchymal – 
epithelial transition (MET), and regain their apical- basal properties (19). 
However, other biological processes such as the development of connective 
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tissue require a cell to undergo only an EMT in which the cells remain in the 
mesenchymal state and form fibroblasts. During an EMT, epithelial cells undergo 
a shift in gene expression that causes them to lose their ability to adhere to each 
other. This results in a loss of epithelial tissues such as those that form the lining 
of the intestinal tract, trachea and kidney tubules (13). The adhesive nature of the 
epithelium is due to the presence of many cell-cell junctions which cause these 
cells to remain in close contact with each other; thus, forming a barrier between 
environments on either side of the tissue. 
 
 
 
Figure 3: Overview of the epithelial-mesenchymal transition. Epithelial cells 
lose their apical-basal properties and become migratory and can intravasate 
and spread to distant sites (24). 
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Although EMT is a normal process during embryonic development and 
tissue regeneration, in patients diagnosed with cancer, this process is 
catastrophic and contributes to metastatic disease. Cells that have undergone 
the transition can intravasate, enter the blood stream and travel to distant sites in 
the body (Figure 3) (12). Signaling cascades such as TGF-β and Wnt activate the 
EMT process by induction of EMT promoting transcription factors such as ZEB1, 
TWIST and Snail (14). The zinc-finger transcription factor Snail is also involved in 
supporting stem-cell like characteristics in HGSOC (15,16). A characteristic of 
cells undergoing EMT is the loss of proteins that form the junctions that are 
responsible for anchoring these cells to one another.  Genes such as OCLN and 
CLDN1 encode the proteins occludin and claudin respectively. Both occludin and 
claudin are trans-membrane proteins that interact with a cytoplasmic protein 
called zona occludens 1 (ZO1) which is encoded by the TJP1 gene. Together, 
these proteins form tight junctions which reside on the apical aspect of the lateral 
borders of cells and contribute to the apical-basal characteristic of epithelial 
tissue (17).   
Other protein complexes, such as adherens junctions, also play a vital role 
in maintaining epithelial tissue integrity. Epithelial cadherin (E-CAD), a protein 
encoded by the CDH1 gene, contains homophilic extracellular regions that form 
bonds with E-CAD proteins on neighboring cells. The cytoplasmic region of E-
CAD interacts with actin filaments via α and β catenins (18). These interactions 
keep epithelial cells firmly in place and allow for tissue formation; thus, loss of 
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these junctions leads to disseminating cells, and in cancer, metastatic disease 
(19). The zinc-finger transcription factor Snail represses the expression of OCLN, 
CLDN1 and CDH1 by binding to E-boxes in their promoter and blocking 
transcription (17). Loss of E-CAD is known to be an indicator of EMT and a factor 
in metastasis. Neural cadherin (N-CAD), encoded by the CDH2 gene, is 
concomitantly upregulated in cells undergoing EMT. In addition, Snail 
upregulates vimentin and fibronectin which are indicative of the mesenchymal 
state. Elevated levels of Snail expression correlate with increased migration, 
invasion and metastasis, and  high Snail expression  is often seen in advanced 
stages of cancer, and correlates with poor prognosis (20).  
Traditionally, an EMT was viewed as a binary process with two phenotypic 
cell populations, epithelial and mesenchymal (19). But it is important to note that 
an EMT is a continuous event that progresses until the transition is complete, 
and at any point in time during this process cells will exhibit an intermediate 
phenotype that is not just epithelial or mesenchymal but somewhere in between 
the two types (21). Recent studies have focused on these intermediate 
phenotypes that exhibit different morphological and transcriptional patterns from 
those at either end of the spectrum and are often referred to as epithelial-
mesenchymal (E/M) hybrid cells (19,22) 
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1.4 The Epithelial-Mesenchymal Hybrid State 
Recently, the focus of EMT and how it contributes to metastatic disease 
has shifted to identifying various sub-types within the EMT spectrum.  This is due 
to the discovery that cancer cells that were traditionally accepted as epithelial or 
mesenchymal co-express  varying levels of epithelial and mesenchymal markers 
(19). Furthermore, cells co-expressing epithelial and mesenchymal markers are 
more migratory, invasive and possess more stem-like properties. Several cell  
markers such as E-CAD, N-CAD, EpCAM, occludin, claudin, ZO1, vimentin, 
CD44, and CD133, as well as transcription factors, Snail and ZEB1, that are 
indicative of the epithelial or mesenchymal phenotype are typically examined to 
determine a cell’s hybrid state (19). In a mouse model of prostate cancer, 
different EMT sub-types were identified by classifying them according to their 
expression levels of EpCAM and Vimentin. These sub-types were divided into:  
EpCAM+ tumor epithelial cells, EpCAM+/Vimentin+ hybrid tumor cells and  
EpCAM-/Vimentin- mesenchymal tumor cells, and It was found that the hybrid 
and mesenchymal subtypes possessed more circulating tumor cells (CTC’s) and 
exhibited more invasive properties (23). The hybrid phenotype is complex and 
poorly understood and the fact that different types of cancers possess their own 
set of markers indicative of the hybrid phenotype, only adds additional 
complexity. For example, ovarian cancer cells that express high levels of CD133 
could further be divided based on localization of the E-CAD protein. Cells that 
were high in cytoplasmic E-CAD but low in membrane E-CAD were deemed 
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hybrid and were found to be tumorigenic when injected into immunodeficient 
mice; serial transplantation of cells from the xenograft tumors continued to 
produce new heterogenous tumors in mice indicating that these cells were 
multipotent and possessed the ability to self-renew (24). The discovery of these 
hybrid states and their potential in contributing to metastatic disease is vital in 
cancer research. Although many strides have been made to understand the E/M 
hybrid phenotype, the mechanisms that mediate the spectrum of phenotypes 
within the EMT program is still poorly understood; continued investigation into the 
characteristics of these hybrid phenotypes is vital in understanding, and 
combating, metastatic disease.  
 
1.5  Breast Cancer Susceptibility Genes (BRCA) and the Use of Poly (ADP-
Ribose) Polymerase Inhibitors to Induce Synthetic Lethality 
 
Of the 22,000 new cases of ovarian cancer that will be diagnosed this 
year, up to 20% of them can be attributed to a harmful mutation in the breast 
cancer susceptibility genes 1 and 2 (BRCA1/2) (25). The BRCA proteins are 
involved in a cell’s DNA damage response in which homologous recombination 
(HR) is employed to repair DNA lesions and maintain genomic integrity. BRCA 
deficient cells lack the ability to perform HR repair and rely on more error-prone 
repair pathways that can lead to genomic instability and tumorigenesis (26). 
Although having a mutation in the BRCA genes increases one’s chances of 
developing ovarian cancer, these mutations have also been associated with 
increased survival and favorable response to platinum-based treatments (5); this 
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can be attributed to the DNA damaging effects of platinum-based drugs and the 
decreased ability to repair the damage which, ultimately, leads to cell death. 
Germline mutations in the BRCA genes are not the only factor that can play a 
significant role in how a patient will respond to chemotherapy. Since up to 50% of 
HGSOC cases exhibit a deficiency in performing HR DNA repair, mutations in 
other HR repair genes as well as epigenetic factors can thwart the effectiveness 
of DNA repair after chemotherapy (26). Poly (ADP Ribose) polymerase (PARP) 
is a protein that is involved in error-prone DNA damage response such as base 
excision repair (BER) and non-homologous end joining (NHEJ), but there is 
evidence that suggests that PARP is active in the HR repair pathway as well 
(27); cells that incur DNA damage but are deficient in HR repair due to BRCA 
mutations, may rely on secondary repair pathways, such as those involving 
PARP, to repair the damage and re-enter the cell cycle. Recently, clinicians have 
taken advantage of this weakness in HR repair by prescribing inhibitors of the 
PARP protein as an adjuvant therapy. PARP inhibition induces cancer cell death 
due to synthetic lethality (in which inactivation of two genes is lethal even though 
single gene inactivation is tolerated). Treatment with PARP inhibitors is 
associated with significant increases in progression-free survival. (28). 
PARP1, a major member of the PARP family of proteins, possesses a 
catalytic function in which it transfers ADP-ribose, a process called poly(ADP-
Ribos)ylation (PARylation), from nicotinamide adenine dinucleotide (NAD+) to a 
target protein (29). PARP inhibitors have been developed based on the molecule 
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nicotinamide, a metabolite of PARylation and a natural inhibitor of PARP. Nearly 
all PARP inhibitors bind to the active site of PARP and inhibit the catalytic 
function (30). This catalytic function helps initiate DNA repair; therefore, 
preventing this process in those with HGSOC that possess a deficient HR repair 
process increases synthetic lethality and results in improved progression free 
survival. PARP has multiple functions in addition to DNA damage repair. For 
instance, PARP has been shown to interact with pluripotency factors such as 
Oct4, Sox2 and Nanog to help maintain pluripotent status (31) as well as stabilize 
the transcription factor Snail which plays a crucial role in tumor metastasis and 
invasion (32). Conversely, the use of PARP inhibitors such as olaparib or 
rucaparib was shown to increase the expression of CD133 and CD117, which 
are both cancer stem cell markers, in ovarian cancer cell lines(33).The exact 
functions of PARP are not entirely understood; additional research into all the 
functions of PARP and its role in cancer is needed to determine if PARP 
inhibitors can play a beneficial role in adjuvant cancer therapy for those that do 
not possess a deficiency in HR repair.  
 
1.6 Working Hypothesis 
  Cancer cells exhibit hybrid phenotypes associated with the epithelial-
mesenchymal transition. A hybrid phenotypic pattern in high-grade serous ovarian 
cancer cells that is associated with tumor invasiveness, chemoresistance, and 
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stem cell like properties can be identified and used as a prognostic indicator of 
patient outcome.    
1.6.1 Specific Aim 1: Characterization of Patient Derived High-Grade Serous 
Ovarian Cancer Cells Based on Properties Associated with the Epithelial-
Mesenchymal Transition 
 
Six patient-derived HGSOC cells and one HGSOC cell line, previously 
characterized and used for comparison (15), were analyzed for epithelial, 
mesenchymal and hybrid morphological characteristics.  
 Cell morphology of all cells used in this study was determined by their 
aspect ratio (width/length) and were analyzed by Qpcr for levels of Mrna 
associated with the epithelial (OCLN, TJP1, CLDN3) and mesenchymal (SNAI1, 
CDH2, FN1) phenotypes. Cell samples were then given an EMT score based on 
mRNA expression levels of these genes.   
1.6.2 Specific Aim 2: Characterization of Patient Derived High-Grade Serous 
Ovarian Cancer Cells Based on Functional Abilities Related to Invasiveness, 
Chemoresistance and Stem-Cell Like Properties. 
 
The self-renewal ability of HGSOC cells used in this study was determined 
using a spheroid forming assay. To determine the invasive capabilities of these 
cells a Transwell assay was performed with inserts coated with basement 
membrane extract. The concentration of cisplatin, a common chemotherapeutic 
drug, needed to inhibit growth by 50% in HGSOC cell samples was determined 
by performing a cell viability assay. Presence of known cancer stem cell markers 
was determined on all HGSOC cell samples by flow cytometry.   
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CHAPTER TWO 
 
CHARACTERIZATION OF PATIENT-DERIVED HGSOC BASED ON 
PROPERTIES ASSOCIATED WITH EPITHELIAL-MESENCHYMAL 
TRANSITION 
 
 
2.1 Materials and Methods 
2.1.1 Cell Culture 
All studies were approved by the Loma Linda University (LLU) institutional 
review board (IRB). Deidentified fresh ovarian cancer samples were provided by 
the Loma Linda University Cancer Center Biospecimen Laboratory (LLUCCBL) 
and were processed by mincing and passing over a 100 μm strainer using the 
plunger of a 3ml syringe. Some fibrous samples were digested with Dispase 
(StemCell Technologies) for 4-16 hours. After pelleting, if a large number of 
erythrocytes was observed, these were removed by overlaying the cell 
suspension on a 3ml Ficoll (Fisher Scientific) gradient. Patient-derived samples 
were cultured in 75% Ham’s F12 (Fisher Scientific) and 25% Dulbecco’s Modified 
Eagle’s Medium (DMEM)(Fisher Scientific) that was supplemented with 5% FBS, 
10uM insulin (Sigma Aldrich), 0.4 M hydrocortisone (Sigma Aldrich), 2 g/mL 
isoprenaline (Sigma Aldrich), 24 g/mL adenine, 100 U/mL of penicillin and 10 
g/mL streptomycin (Genesee Scientific). 5-10 uM Y27632 (Reagents Direct) was 
added to establish growth in vitro. Low passage (<10) patient derived cells were 
used to avoid changes induced by extensive passaging in in vitro culture. 
OVCAR8 cells were cultured in Dulbecco’s Modification of Eagle’s Medium 
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(DMEM) with 10% fetal bovine serum (FBS), 2mM L-Glutamine, 100 U/mL 
penicillin, and 10 g/mL streptomycin. 
 
2.1.2 Morphological Measurements and EMT Score 
Aspect ratio was calculated using ImageJ to measure length and width; 
aspect ratio = width/length. We calculated EMT score by using qRT-PCR levels 
of three epithelial (OCLN, TJP1, CLDN3) and three mesenchymal (SNAI1, 
CDH2, FN1) markers selected on the basis of the minimal number of factors able 
to predict E vs. M status in agreement with morphological characteristics 
(Chirshev, et al, in revision).  We modified the formula used by Chae et. al, 
substituting z score with expression of RNA markers relative to housekeeping 
gene β-actin and subtracting epithelial markers from mesenchymal markers (34): 
EMT score = Mean of mesenchymal markers – mean of epithelial markers. 
Human BJ1 fibroblasts and MCF10A samples served as mesenchymal and 
epithelial controls, respectively. 
 
2.1.3 Real-time Quantitative Reverse-transcription PCR (qRT-PCR) 
Total RNA from cell culture samples were isolated using Trizol reagent 
(Life Technologies, Carlsbad, CA) according to manufacturer’s instructions. 1μg 
of RNA was used to synthesize cDNA using Maxima first strand cDNA synthesis 
kit (K1672; ThermoFisher Scientific, Grand Island, NY, USA). Real-time qPCR for 
mRNA was performed using PowerUP SYBR Green master mix (ThermoFisher 
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Scientific, Grand Island, NY, USA) on a Stratagene Mx3005P instrument (Agilent 
Technology, Santa Clara, CA, USA).  Epithelial and mesenchymal primers used 
were claudin, ZO1, occludin, snail, fibronectin and N-CAD (Table 1). mRNA 
expression of all genes was normalized to actin. 
 
Table 1: RT-qPCR primers used in this study 
Primer Sequences used in RT-qPCR 
Actin F 5'-TGA AGT GTG ACG TGG ACA TC-3' 
Actin R 5'-GGA GGA GCA ATG ATC TTG AT-3' 
Claudin F 5'-TTC ATC GGC AGC AAC ATC ATC-3' 
Claudin R 5'-CGC CTG AAG GTC CTG TGG-3' 
Occludin F 5'-TCA GGG AAT ATC CAC CTA TCA CTT CAG-3' 
Occludin R 5'-CAT CAG CAG CAG CCA TGT ACT CTT CAC-3' 
ZO1 F 5'-AGG GGC AGT GGT GGT TTT CTG TTC TTT C-3' 
ZO1 R 5'-GCA GAG GTC AAA GTT CAA GGC TCA AGA GG-3' 
Fibronectin F 5'-GCC TAA GCA CTG GCA CAC AAC AGT TT-3' 
Fibronectin R 5'-ACT GCC ATT GAT GCA CCA TCC AAC-3' 
NCAD F 5'-GAG GAG TCA GTG AAG GAT TCA-3' 
NCAD R 5'-GGG AAG TTG ATT GGA GGG ATG-3' 
Snail F 5'-CAC TAT GCC GCG CTC TTT-3' 
Snail R 5'-GGT CGT AGG GCT GCT GGA-3' 
   
           
2.1.4 Western Blot 
Cells were lysed in Laemmli buffer, sonicated, and proteins were 
separated by SDS-PAGE and transferred to a PVDF membrane. To prevent non-
specific binding, the membrane was blocked with 0.1%-5% milk TBST for 1 hour 
for each immunoblotting antibody. Immunoblotting was performed with primary 
antibodies including: α/β-tubulin, LIN28A, and HMGA2 (Cell Signaling 
Technology, Danvers, MA, USA). Secondary antibody immunoblotting was done 
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with anti-rabbit IgG conjugated with Dylight 680 (Invitrogen, Carlsbad, CA, USA). 
PVDF membranes were imaged by Odyssey LI-COR Infrared Imaging System 
(LI-COR Biosciences, Lincoln, NE, USA). Densitometry analysis was performed 
by ImageJ software (National Institutes of Health, Bethesda, MD, USA). 
 
2.2 Results 
2.2.1 Morphological Characteristics of Patient-Derived HGSOC Cells 
This study was conducted using six patient derived samples (PDX5, 
PDX9, PDX3, PDX8, PDX6 & PDX4) and one HGSOC cell line (OVCAR8). 
These cells were first analyzed based on their morphology by obtaining phase 
contrast micrographs and then determining the cells’ aspect ratio. Cells that are 
more epithelial possess more cell-cell adhesion molecules and will grow tightly 
packed next to one another exhibiting a spherical, cobblestone-like appearance. 
On the other hand, cells that are more mesenchymal in nature appear elongated 
or spindle-like and lack the cell-cell contact seen in epithelial cells (22) (Figure 
4A). The spherical vs. elongated morphology can be quantified by determining 
the aspect ratio (width/length) of the cells; cells that are epithelial will have a ratio 
closer to 1.0, and the more elongated, mesenchymal features a cell exhibits, the 
lower the ratio. After quantification of morphology, cells were placed in order from 
most mesenchymal (PDX5) to most epithelial (PDX4) according to the measured 
ratio (Figure 4B). 
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Figure 4: Morphological 
characteristics of cells used in this 
study A) Phase contrast 
micrographs of cells in order from 
most epithelial to most 
mesenchymal. B) Aspect ratio of 
cells determined by dividing cell 
width by cell length. Cells were 
placed in order of high to low 
aspect ratio left to right; n=3, error 
bars +/- SEM. Work performed in 
collaboration with Evgeny 
Chirshev (Chirshev, et al., in 
revision). 
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2.2.2 Epithelial-Mesenchymal Status of Patient Derived Serous Ovarian Cancer 
Cells 
 
Cells that are undergoing EMT will co-express markers that are 
associated with the mesenchymal state as well as markers associated with the 
epithelial state and are referred to as EMT hybrid cells (26).  In order to 
determine the relationship between morphology and gene expression, RT-qPCR 
was performed to determine mRNA levels of three epithelial markers (OCLN, 
TJP1, CLDN3) and three mesenchymal markers (SNAI1, CDH2, FN1) (Chirshev, 
et al., in revision) Expression levels of these six markers were used to develop 
an EMT score that quantitatively depicts the point on the EMT continuum the 
cells reside. Cells that are closer to the mesenchymal end of the EMT spectrum 
yield a positive EMT score; whereas, cells that are on the epithelial end of the 
spectrum generate a negative EMT score. Cells in which the EMT score is close 
to zero may indicate a hybrid phenotype (Figure 5).  BJ1, human fibroblast cell 
line, was used as a mesenchymal control (MC) and MCF10A, a normal breast 
epithelial cell line, was used as an epithelial control (EC). The EMT score 
negatively correlates with the cell’s aspect ratio (Figure 4B) with Spearman’s 
correlation coefficient of 0.79.   
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Figure 5: EMT Score. Three epithelial (OCLN, TJP1, CLDN3) and three 
mesenchymal markers (SNAI1, CDH2, FN1) were used to develop an EMT 
score. Cells that have a positive EMT score are more mesenchymal while 
cells that have a negative EMT score are more epithelial. MCF10A was used 
as a epithelial control; BJ1 used as a mesenchymal control (n=3) 
 
 
 
To further understand the EMT status of our patient derived cells beyond 
mRNA expression, flow cytometry was performed to assess the levels of cell 
adhesion molecules NCAD, a mesenchymal marker, and ECAD, an epithelial 
marker as well as the zinc finger transcription factor Snail.  All samples exhibited 
expression of both NCAD and ECAD, but three cell samples that were placed 
morphologically in the middle of the spectrum exhibited the biggest difference 
between expression of NCAD and ECAD. One of our samples that 
morphologically appeared more epithelial, PDX6, exhibited the highest 
percentage (49.4%) of double positive cells, whereas, ovarian cancer cell line, 
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OVCAR8, exhibited a double positive population of 1.96% (Figure 6A & 6B). The 
zinc finger transcription factor Snail promotes the EMT process by repressing  
the expression of epithelial cell-cell adhesion molecules ECAD, occludin and 
claudin. Levels of the Snail protein present in our cell samples, relative to tubulin, 
was assessed by western blot.  Snail protein was detected in all patient derived 
cell samples as well as OVCAR8, although at varying levels (Figure 6C & 6D). 
Morphological analysis, EMT score and Snail expression was performed 
in collaboration with Evgeny Chishev.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.                                                                                                           B.          
   NCCIT     PDX4    PDX6    PDX8    OV8    PDX9     PDX5    PDX 3    FTSEC    
 
Tubulin 
 
Snail 
C.                                                                                                    D. 
Figure 6: Expression of adhesion molecules and transcription 
factor snail. A) Percentage of cells expressing  N-cadherin and 
E-Cadherin. B) Percentage of cells double positive for both 
adhesion molecules.  Western blot analysis of the Snail 
protein. C) Quantification of Snail protein levels relative to 
tubulin obtained by western blot. D) Image of western blot 
done in this study. NCCIT = pluripotency control; fallopian tube 
secretory epithelial cell (FTSEC) = normal control. 
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CHAPTER THREE 
 
CHARACTERIZATION OF PATIENT-DERIVED HGSOC CELLS BASED ON 
FUNCTIONAL ABILITIES RELATED TO INVASIVENESS, 
CHEMORESISTANCE AND STEM-CELL  
LIKE PROPERTIES 
 
3.1 Materials and Methods 
3.1.1 Flow Cytometry 
After trypsinization and counting, cells were placed in FACS stain 
(phosphate-buffered saline (PBS) with 1% FBS, 0.1% Sodium Azide and 2mM 
EDTA) and labelled with conjugated fluorescent dye antibodies against CD44 
(130-110-298), CD117 (130-099-325), CD133 (130-090-854), CD324 (E-
Cadherin) (130-099-141) obtained from Miltenyi Biotec (Auburn, CA). CD325 (N-
Cadherin) (350814; BioLegend, San Diego, CA) were also used to label cells. 
The MACSQuant Analyzer 10 (Miltenyi Biotec, Auburn, CA, USA) was used for 
flow cytometry. FlowJo Version 10 (FlowJo LLC, Ashland, OR, USA) was utilized 
for data analysis. Forward scatter and side scatter were used to determine intact 
population. Subsequent gating against forward scatter-area and forward scatter-
height was used to isolated single cell populations. Single positive, double 
positive and triple positive populations were gated based on isotype (Figure 7). 
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Figure 7: Gating strategy used in flow cytometric analysis of cell surface 
markers.  Isotype (left column) and experimental (right column). A) Isolation of 
intact population and single cell population. B) Single positive gates for CD44, 
CD133 and CD117. C) Double positive and triple positive gates. D) Single 
positive and double positive for cell surface markers N-CAD and E-CAD.  
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3.1.2 Cell Viability Assay 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-
Aldrich, St. Louis, MO, USA) assays were used to determine cell viability. Cells 
were seeded at a density of 1000 cells/well in 96-well plates and incubated 
overnight. The cells were then treated with increasing concentrations of cisplatin 
for 72 hours. After drug treatment, MTT solution was added to each well, and the 
plates were incubated for 2 hours at 37 °C. The formed formazan crystals were 
dissolved in dimethyl sulfoxide (DMSO), and the absorbance was measured at 
570 nm using a SpectraMax i3x microplate reader (Molecular Devices, 
Sunnyvale, CA, USA). The half-maximal inhibitory concentration 203 (IC50) of 
drug was analyzed using the GraphPad Prism Version 7.0 (GraphPad Software, 
La Jolla, CA, USA). 
 
3.1.3  Spheroid Assay 
Cells were plated at a density of 1,000 cells/mL in non-tissue culture 
coated plates and maintained for 7 days in serum-free medium (DMEM/F12 
50/50) supplemented with 0.4% bovine serum albumin, 10ng/mL FGF, 20ng/mL 
EGF, 6.7ng/ml selenium, 5.5ug/ml transferrin, 10ug/ml insulin, and 1% knock out 
serum replacement (Gibco/ThermoFisher Scientific). Seven days later the 
number of spheroids was counted and statistically analyzed. Phase contrast 
images of spheroids were taken and analyzed using ImageJ software (National 
Institutes of Health, Bethesda, MD, USA) to assess the size of spheroids. 
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3.1.4 Transwell ® Invasion Assay 
Prior to assay, cells were cultured for 24 hours in their respective media 
without FBS. Transwell inserts were coated with 0.1μg Basement Membrane 
Extract (BME) (3433-010-01) in 1X Cultrex coating buffer (3455-096-03) 
(Trevigen, Gaithersburg, MD) and placed in incubator for 24 hours.  On the day 
of the assay, cells were dissociated from culture dish with 0.05% Trypsin/EDTA, 
counted and resuspended in serum free media.  20,000 cells (PDX4 & PDX6) & 
50,000 cells (PDX3, PDX5, PDX9, PDX8 & OVCAR8) in 200μL of serum free 
media were plated on three inserts; two coated with BME and one not coated. 
Media containing FBS was added to the bottom chamber of one well containing a 
BME coated insert and another well that contained the non-coated insert. Media 
without FBS was added to the bottom chamber of the well that contained the 
second BME coated insert. Cells were placed in a 37⁰C incubator for 24 hours. 
Media was removed from inserts and the bottom wells and top of inserts were 
wiped clean with a cotton tipped applicator then inserts were fixed in 70% ethanol 
for 15 minutes.  Once fixed, inserts were placed in 0.2% crystal violet stain for 
10-15 minutes and rinsed with dH20. Once dry, cells on bottom of insert were 
imaged at a total magnification of 100x using Leica DMi1 inverted microscope 
and counted using ImageJ. Samples in which 50,000 cells were plated onto 
insert were normalized to 20,000. 
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3.2 Results 
3.2.1 Invasive Capabilities of Patient Derived HGSOC Cells 
HGSOC is such a deadly disease due to the fact that diagnosis is usually 
obtained in the later stages of the disease when malignant or metastatic stages 
are present (2).  Cells must undergo EMT to successfully invade surrounding 
tissues and form metastases at sites distant from the area of primary tumor 
formation. In order to characterize the six patient samples used in this study, a 
Transwell ® invasion assay was performed using a membrane with 5µM pores 
coated with 0.1µg/mL basement membrane extract (BME). OVCAR8, the 
HGSOC cell line, exhibited the highest number of cells capable of invading 
through BME. Since OVCAR8 also had an EMT score closest to zero, which 
indicates the most hybrid phenotype, this result is not surprising. Additionally, 
patient derived cells with a positive EMT score (PDX5, PDX9, & PDX3) also 
showed increased invasive capabilities compared to cells with a negative EMT 
score (PDX4 & PDX6) (Figure 8A & 8B).  
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3.2.2 Chemoresistance of HGSOC Patient Derived Ovarian Cancer Cells 
Use of cisplatin and paclitaxel is the standard combinatorial therapy for 
those with HGSOC. In this study, we used a cell viability assay to determine the 
Figure 8: Transwell Invasion Assay. A) Average number of cells per field of view (n=3) 
that were capable of invading through a BME coated insert (n=3; error bars are +/- 
standard deviation). B) Images of Transwell ® inserts after staining    
A. 
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concentration of chemotherapeutic drug needed to inhibit cell growth by 50%. 
Cells that had a high EMT score showed a greater resistance to cisplatin (Figure 
9A). It should be noted that 3 cell samples that scored a high EMT score (PDX9, 
OVCAR8, PDX3) and showed increased resistance to cisplatin, were BRCA1/2 
wild type (Figure 9B). Since the BRCA proteins are involved in homologous 
recombination during the DNA repair process (32), the cells’ ability to resist the 
harmful effects of these drugs is expected. Additionally, cells that showed 
increased sensitivity have lower EMT scores and possess mutations in the 
BRCA2 gene. 
 
 
A. 
 
B. 
 
Sample 
IC50, 
Cisplatin (μM) 
BRCA 
Status 
PDX4 0.7 BRCA2 Mutation 
PDX6 0.4 BRCA2 Mutation 
PDX8 1.5 Unknown 
PDX3 6.7 WT 
OVCAR8 5.5 WT[70]* 
PDX9 6.2 WT 
PDX5 4.1 BRCA1 Mutation 
   
Figure 9: Chemosensitivity of patient derived HGSOC samples. A) MTT assay 
showing cell viability at increasing concentrations of cisplatin. B) IC50 values 
and BRCA status of the cells used in this study. (n=3; error bars are +/- SEM) 
(Chirshev, et al., in revision). 
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3.2.3 Stem-Cell Like Characteristics of HGSOC Patient  
Derived Ovarian Cancer Cells 
 
Stem cells possess unique properties such as the ability to differentiate 
and self-renew. Tumors are heterogeneous and contain both differentiated cells 
and and CSC  that may have the capacity to form new tumors at distant sites 
((8)To determine self renewal ability, a spheroid assay was utilized. Surprisingly, 
cells with a high EMT score (PDX5, PDX9 and PDX3) formed few to no 
spheroids. But the cells with a lower EMT score were able form more and larger 
spheroids compared to the more mesenchymal cell samples (Figure 10A & 10B). 
 
 
 
 
 
 
 
 
Figure 10: Spheroid assay. Performed in non-adherent conditions. Spheroids 
were counted and measured on day 7. A) Number of spheroids formed per 1000 
cells. B) Spheroid size. (n=3; error bars are +/- SEM) (Chirshev, et al., in 
revision).  
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Cancer cells that possess stem-like characteristics such as self-renewal 
and differentiation capabilities can be identified and isolated according to the 
molecules that are present on the cell surface. In ovarian cancer, those markers 
have been identified as CD44, CD133 and CD117 ((35) and levels of these cell 
surface molecules were assessed in our patient derived samples using flow 
cytometry. Although CD44 was expressed in all our cell samples, 86% - 98% of 
PDX3, PDX5 and OVCAR8 cells were positive for this marker, whereas, the 
percent of the population positive in PDX4, PDX6, PDX8 and PDX9 was only 2% 
- 18%. (Figure 11A) 
Cancer stem cells cannot be identified solely on the presence of one cell 
surface marker. Since CSC express multiple markers simultaneously, our 
samples were examined for their double positive population of two CSC markers, 
CD133 and CD117, and their triple positive population consisting of CD44, 
CD133 and CD117. The patient sample PDX8 exhibited the highest percentage 
of both double positive and triple positive cells with % expression of 2.5% and 
0.37% respectively. Interestingly, OVCAR8 showed the least expression of 
double positive (0.05%) and triple positive (0.04%) (Figure 11D & 11E). 
Spheroid assay and cell viability assay was performed in collaboration 
with Evgeny Chirshev.  
  
33 
 
A. 
 
B. 
 
C. 
 
 
 
 
 
 
34 
 
 
D. 
 
Figure 11: Flow cytometry of cell surface molecules present in cancer stem-like cells. 
A) CD44+ B) CD133+ C) CD117+ D) CD133+/CD117+ E) Triple + (n=3; error bars are 
+/- standard deviation) 
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CHAPTER FOUR 
 
EFFECTS OF PARP INHIBITION IN PATIENT-DERIVED HGSOC CELLS 
 
4.1 Materials and Methods 
4.1.1 Olaparib Treatment 
 Cells were cultured according to protocol stated in cell culture 
methods. Before treating cells with inhibitor, cells were passaged into a 6-well 
tissue culture plate and incubated for 24-hours. Olaparib (Catalog # S1060, 
Selleckchem, Houston, TX) was reconstituted with DMSO to a working 
concentration of 5mM. After 24-hour incubation, olaparib was added to cell 
culture medium to final concentrations of 5.67uM, 12uM, 17uM or 50uM. Cells 
were left to incubate with treated medium for 24, 48 or 96 hours. Subsequently, 
cells were dissociated from culture dish with 0.05% Trypsin/EDTA and collected 
for qRT-PCR and Flow cytometry.  
4.2 Results 
4.2.1 mRNA Expression Levels of PARP, Snail and Oct4 after Treatment with 
PARP Inhibitor  
 
In order to determine if treating ovarian cancer cells with an inhibitor of the 
PARP protein would affect gene expression of Snail and Oct4 at the transcription 
level, RT-qPCR was performed on OVCAR8, a HGSOC cell line, after treatment 
with 12µM of olaparib for 24 hours (Figure 12A).   
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A.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 12: Expression of PARP, Snail and Oct4 mRNA post olaparib 
treatment via RT-qPCR. (n=3, exception: Snail expression n=2; error bars 
are +/- standard deviation).  
 
 
OVCAR8 cells were subsequently treated with olaparib at 5.76µM, 17µM 
and 50µM for 48 and 96 hours (Figure 13A – 13F). After 24 hours of treatment 
with olaparib, the transcription level of Snail increased. Significance cannot be 
determined due to having only two treated samples. However, among the 
samples treated for 48 and 96 hours, mRNA expression level of Snail increased 
significantly only when treated at the highest dose (50µM) for the longest length 
of time (96 hours), whereas mRNA expression of PARP and POU5F1, the gene 
that encodes for the OCT4 protein, were not significantly affected by PARP 
inhibition at any concentration for any length of time (Figure 12 & 13A – 13F). It is 
unclear as to the cause of the decrease in mRNA transcripts when cells were 
treated with 17µM of olaparib for 48 hours. Since much is still not known about 
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the functions of the PARP protein, more research into its affects on cancer cells 
will need to be done.  
 
 
A. 
 
B. 
 
C. 
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D. 
   
E. 
 
F. 
     
 Figure 13: Expression of PARP, Snail and Oct4 
mRNA post olaparib treatment A,B, C) 48 hours A) 
50µM B) 17µM C) 5.67µM. OVCAR8 treated with 
olaparib for D,E,F) 96 hours D) 50µM E) 17µM F) 
5.67µM. (n=3; error bars are +/- standard deviation) 
 
39 
 
4.2.2 Expression of Cancer Stem Cell Markers CD44, CD133 and CD117 after 
Treatment with a PARP Inhibitor 
 
There is some evidence to suggest that treating ovarian cancer cells with 
olaparib will enrich the population with CD133+ and CD117+ cells indicating a 
more stem cell-like phenotype (33). After olaparib treatment OVCAR8 cells were 
analyzed by flow cytometry for levels of CD44, CD133 and CD117. After 24 
hours of olaparib treatment (12µM) there was a significant increase in both 
CD133+ and CD117+ cells but no increase in CD44+ cells (Figure 14A). Cells 
were also analyzed for double positive (CD133 & CD117) and triple positive 
(CD44, CD133 & CD117) populations. Although the average double and triple 
positive population increased, this increase was not statistically significant 
(Figure 14B & 14C).  
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A.  
B.  
 
 
C.  
 Figure 14: Expression of cancer stem cell markers after 
treatment with 12µM  olaparib for 24 hours.  A) % of cells 
positive for CD133, CD117 or CD44 B) % of cells double positive 
for CD133 and CD117. C) % of cells triple positve for CD44, 
CD133 and CD117. (n=3; error bars are +/- standard deviation) 
OVCAR8 – 24 Hours 
OVCAR8 – 24 Hours 
CD44+/CD133+/CD117+ 
OVCAR8 – 24 Hours 
CD133+/CD117+ 
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In order to determine how different concentrations of olaparib at extended 
incubation times would affect gene expression of these cancer stem cell markers, 
OVCAR8 cells were treated at a starting concentration of 50µM for 48 and 96 
hours. Olaparib concentrations were reduced three-fold to 17µM, then reduced 
three-fold a second time to 5.67µM where they were incubated at both 
concentrations for 48 and 96 hours. Upon treating these cells for 48 hours at a 
concentration of 50µM, only CD133 increased significantly (Figure 15A). 96 
hours of treatment at a 50µM concentration resulted in a significant decrease in 
CD44+ cells, double positive (CD133/CD117+) cells and triple + 
(CD44+/CD133+/CD117+) cells (Figure 16A-C) which could indicate cell death at 
this high dose for the extended period of time. At a higher concentration of 
olaparib, 17µM, a significant increase was seen in the cancer stem cell marker 
CD133 after 48 hours (Figure 15B)  and 96 hours (Figure 16B) of treatment, but 
CD117 increased significantly only after 96 hours of treatment. At the lowest 
concentration, 5.67µM, the only significant change was a very small magnitude 
increase in CD44 expression after 96 hours of treatment (Figure 16G).  
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5.67µM 
G.  
H.  
I.  
 Figure 15: Expression of cancer stem cell markers after olaparib 
treatment for 48 hours. A,B,C) 50µM A) Single positive B) Double 
positive for CD133 and CD117. C) Triple positive for CD44, 
CD133 and CD117. D,E,F) 17µM D) Single positive E) Double 
positive for CD133 and CD117. F) Triple positive G,H,I) 5.67µM G) 
Single positive  H) Double positive for CD133 and CD117. I) Triple 
positive (n=3; error bars are +/- standard deviation) 
Ovcar8 - 48 Hours 
Ovcar8 - 48 Hours 
Ovcar8 - 48 Hours 
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50µM 
A.  
B.  
C.  
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17µM 
D.  
E.  
F.  
 
 
 
 
Ovcar8 – 96 Hours 
CD44+/CD133+/CD117+ 
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5.67µM 
G.  
H.  
I)  
 Figure 16: Expression of cancer stem cell markers post 
olaparib treatment for 96 hours. A,B,C) 50µM A) Single 
positive B) Double positive for CD133 and CD117. C) 
Triple positive for CD44, CD133 and CD117. D,E,F) 
17µM D) Single positive E) Double positive for CD133 
and CD117. F) Triple positive G,H,I) 5.67µM G) Single 
positive  H) Double positive for CD133 and CD117. I) 
Triple positive. (n=3; error bars are +/- standard 
deviation) 
Ovcar8 – 96 Hours 
Ovcar8 – 96 Hours 
Ovcar8 – 96 Hours 
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CHAPTER FIVE 
 
DISCUSSION AND CONCLUSIONS 
 
5.1 Discussion 
In this study, we examined six patient derived HGSOC cell samples and 
one HGSOC cell line, OVCAR8, which was used for comparison. The goal of this 
study was to identify a phenotypic pattern within these samples that is associated 
with invasiveness, chemoresistance and the ability to self-renew and 
differentiate. Cancer cells that possess these characteristics have been closely 
associated with the epithelial-mesenchymal transition, in particular, the epithelial-
mesenchymal hybrid. In previous studies, cells that exhibit an epithelial-
mesenchymal hybrid (E/M hybrid) phenotype exhibited more invasiveness, 
chemoresistance and stemness. Throughout this study, the EMT status of these 
samples was examined in conjunction with their abilities to invade through an 
extra-cellular matrix, resist the effects of chemotherapeutic drugs and perform 
stem cell like functions such as self-renewal and differentiation.  
 
5.1.1  Epithelial-Mesenchymal Status of Patient Derived High Grade Serous 
Ovarian Cancer Cells 
 
In this study, our cell samples were examined based on their 
morphological features, cobblestone or spindle shaped, and mRNA expression 
levels of three mesenchymal markers (SNAI1, CDH2, FN1) and three epithelial 
markers (OCLN, TJP1, CLDN3). Using data from the morphological and mRNA 
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expression analysis, the cells used in this study were placed in order from most 
epithelial to most mesenchymal (PDX4, PDX6, PDX8, OVCAR8, PDX9 & PDX5). 
In a previous study that characterized HGSOC cell lines, although all were E/M 
hybrid, OVCAR8 was the most mesenchymal (15). However, in this study the 
patient derived HGSOC cells exhibited a much broader phenotype; here, 
OVCAR8 was place in the middle of the spectrum with two patient derived 
samples (PDX9 & PDX5) exhibiting more mesenchymal features and scoring a 
higher EMT score than OVCAR8 (Figures 5 & 6). The two samples that scored 
the lowest score, PDX4 & PDX6, are the most epithelial samples in the panel; 
EMT score agrees with the morphological features of all the cells in the panel.  
Although extremely useful, cell lines that have existed in culture for many years 
can undergo many shifts in their gene expression, mutations, chromosomal 
abnormalities and loss of cellular diversity could ultimately lead to a phenotype 
switch that is much different from the primary tumor from which they were 
derived. The broad phenotypic range of the patient derived cells used in this 
study more accurately depicts the disease that manifests in patients, thus, 
providing more reliable data that could provide insight into the mechanisms of 
this disease.  
We observed several characteristics of the hybrid phenotype in all 
samples examined. Our samples exhibit a morphologically diverse phenotype 
that ranges in appearance from epithelial (cobblestone) to mesenchymal 
(spindle-like), but all samples, even the most epithelial in appearance, express 
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the transcription factor Snail which promotes EMT. Furthermore, all cells in our 
panel co-express cell-surface proteins N-CAD and E-CAD and are transcribing 
epithelial genes, OCLN, TJP1 & CLDN3, as well as mesenchymal genes, SNAI1, 
CDH2 & FN1.  
 
5.1.2 Functional Characteristics of HGSOC Patient Derived Cells and EMT 
Hybrid Status 
 
The ability of cancer cells to invade nearby tissues and disseminate 
throughout the body is the most detrimental characteristic of the disease. These 
cells  often possess enhanced mechanisms that aid in their survival during 
chemotherapy. In this study, OVCAR8 was the most invasive sample with 
approximately 600 cells per field of view that invaded through the basement 
membrane extract. In the patient derived cells, PDX4, PDX6, PDX8, PDX3, 
PDX9 & PDX5, number of cells per field of view was 35, 3, 12, 135, 95 & 70 
respectively (Figure 8). Interestingly, PDX3 and PDX9 were also the most 
chemoresistant with IC50 concentrations of 6.7µM and 6.2µM respectively 
(Figure 9).  
 Of the patient derived samples in this panel, those that scored a higher 
EMT score were more robust in invading through the basement membrane 
extract and possessed a greater ability to evade the harmful effects of cisplatin 
(Figure 9) compared to cells with an EMT score that was less than zero.  
Strikingly, this relationship is not seen in relation to self-renewal and 
differentiation. The more mesenchymal cells, PDX3, PDX9 & PDX5, that scored 
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an EMT score greater than zero formed little to no spheroids. In contrast, the 
cells with EMT scores below zero, PDX4 & PDX6, produced 411 and 79 
spheroids per 1000 cells plated, respectively. The most and the largest spheroids 
were produced by PDX8 (584), with an EMT score greater than zero and is 
placed at the mid-point of the EMT process (Figure 10). The trend in the 
increasing number and size of spheroids from the cells characterized as more 
epithelial toward the cells characterized at the mid-point of the EMT process is 
repeated in flow cytometry.  Flow cytometry data shows the percentage of cells 
double positive for CD133 & CD117 increase toward the mid-point.  Although all 
cell samples contained a double positive population, PDX4, PDX6 & PDX8 
possessed the highest percentage of double positive at 0.63%, 0.81% and 2.5% 
respectively. Since the double positive population may be indicative of  cancer 
stem cells, it makes sense that these samples also formed the most and the 
largest spheroids. As placement moves toward the mesenchymal end of the 
spectrum, the double positive population drops to below 0.5% with OVCAR8 
having the least percentage at 0.05%.  
  Invasiveness, chemoresistance and stem cell-like characteristics are not 
mutually inclusive characteristics in HGSOC E/M hybrid cells. Instead, a subset 
of these characteristics, invasiveness and chemoresistance, are more indicative 
of a hybrid phenotype closer to the mesenchymal end of the spectrum, whereas, 
cells that possess stem cell like characteristics such as self-renewal and 
differentiation tend to be closer to the epithelial end of the spectrum. It should be 
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noted that cells that undergo EMT will also undergo a mesenchymal-epithelial 
transition (MET) in which they undergo a phenotypic switch in the opposite 
direction. A MET is necessary for migratory cells to attach to distant sites and 
form metastases. In order to adhere to tissues and form cell aggregates, the 
expression of cell-cell adhesion molecules would again be upregulated. It is 
unclear if PDX4, PDX6 and perhaps PDX8 have completed the EMT process and 
are now undergoing MET or if they are just beginning the EMT transition, but it is 
clear that all of these cells are in a E/M hybrid state, and as they move through 
the EMT or MET continuum, they have the ability to gain and lose some of the 
most detrimental characteristics of HGSOC.  
 Chemoresistance is a characteristic that is associated with cells that 
exhibit stem cell-like capabilities, but the cells used in this study that possessed 
the most stem cell-like properties were more sensitive to cisplatin. It should be 
noted, however, that two samples, PDX4 and PDX6, possess mutations in the 
gene for BRCA2 which would cause them to perform HR repair inefficiently and 
thus be more sensitive to cisplatin. The BRCA status of PDX8 is not known. 
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5.1.3 Effect of Olaparib on Snail and CSC Markers 
 The use of PARP inhibitors as an adjuvant therapy has become 
increasingly common because of its success in increasing progression-free 
survival (28). Despite initial success, some patients develop resistance to PARP 
inhibitors and eventually succumb to the disease (36). Previous studies have 
implicated the PARP protein in stabilization of Snail; therefore, inhibition of the 
PARP protein should destabilize Snail and subsequent homeostatic mechanisms 
might be expected to increase expression of Snail mRNA. An increase in the 
mRNA expression of Snail was seen in OVCAR8 when treated with Olaparib for 
24 hours at 12µM, 48 hours at 5.67µM, 96 hours at 17µM, as well as 48 and 96 
hours at 50µM, but this increase was only significant when treated for 96 hours at 
50µM. However, because levels of Snail mRNA are lower, although difference in 
levels were not significant, in cells treated for 96 hours at 5.67µM and for 48 
hours at 17µM, PARP’s role in Snail stabilization and PARP inhibitors role in 
ameliorating this stabilization remains unclear and additional research is needed. 
 Previous studies have shown that treatment with PARP inhibitors such as 
olaparib enriched for cancer stem cell markers CD133 & CD117. This result was 
recapitulated in OVCAR8 when treated with olaparib. At the lowest concentration 
of olaparib, 5.67µM, no significant increase in the markers existed after 48 hour 
and 96 hours of treatment. However, when treated with the higher 
concentrations, 17µM (48 and 96 hours) and 50µM (48 hours), the percentage of 
CD133 positive cells increased significantly. A significant increase in the 
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percentage of the population positive for CD117 occurred at a concentration of 
17µM when treated for 96 hours. Interestingly, at all concentrations and 
treatment intervals, neither the double positive population (CD133+/CD117+) nor 
the triple positive population (CD44+/CD133+/CD117+) increased significantly 
indicating that the enrichment of the CD133 positive population by olaparib 
treatment is irrespective of the presence of CD117. However, at the highest dose 
(50µM) and the longest treatment interval (96 hours), the double positive 
population and the triple positive population decreased significantly. This 
decrease could be attributed to the high concentration and extended exposure to 
olaparib resulting in cell death of all cell types within the population.  
 The significant increase in the population positive for CSC marker CD133 
when treated for 24 hours at 12µM (Figure 14A), 48 and 96 hours at 17 µM 
(Figures 15D & 16D) and 48 hours at 50 µM (Figure 15A) may reflect the 
enhanced ability for cancer stem cells to perform DNA repair. Since these cells 
were only treated with olaparib and not treated with a common chemotherapeutic 
drug such as cisplatin, nor do these cells possess mutations in the BRCA genes, 
an enriched population post-treatment may indicate that  olaparib possesses its 
own cytotoxic effects on cells that lack CD133 or, perhaps, the use of olaparib 
up-regulates the expression of CD133.  
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5.2 Conclusions 
 In the HGSOC samples studied, the functional characteristics of the cells 
was determined according to their placement on the EMT/MET continuum. The 
data suggests that the most detrimental characteristics of HGSOC are shared 
among the various states of EMT. Cells that are more invasive and 
chemoresistant reside closer to the mesenchymal end of the continuum, whereas 
cells that express higher levels of CSC markers, such as CD133 and CD117, and 
are more tumorigenic are of the hybrid sub-type. This adds another level of 
complexity to the disease which already claims many lives of those diagnosed. 
To accurately target this disease, continued research is essential to understand 
the mechanisms that cause plasticity in HGSOC. In addition, accurately 
determining where  in the EMT/MET process HGSOC cells currently reside could 
be a valuable prognostic tool as well as a tool in developing personalized 
treatment plans.  
The use of PARP inhibitors has been valuable in delaying disease 
recurrence in those with afflicted HGSOC, but many functions of the PARP 
protein are still relatively unknown. The enrichment of cells that possess the CSC 
marker CD133 may be a clue as to why benefits from PARP inhibitors are 
temporary.  In order to draw a conclusion, further research into the effects 
olaparib, and other PARP inhibitors,  have on CD133 needs to be performed. 
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